Autopsy report · NCT05654870

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

“Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Neurocrine Biosciences

Sponsor type

Industry

Conditions

Schizophrenia

Interventions

Valbenazine; Placebo

Participants

8

Sites

3

Countries

United States

Trials that died the same way

• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  “The study was closed due to the end of funding.” (60% match in meaning)
• AZD1222 Vaccine for the Prevention of COVID-19
  “The study was put on hold in September 2020 due to a safety concern in another trial but never restarted. In the meantime our clinical development program now includes a similar study with a different design, which we prefer to complete now.” (59% match in meaning)
• Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome
  “Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.” (59% match in meaning)
• Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
  “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.” (58% match in meaning)
• Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease
  “Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.